Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. It is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Potential benefits include:

• Tesamorelin stimulates the pituitary gland to produce and release growth hormone. • Increased H levels lead to increased levels of insulin-like growth factor-1 (IGF-1).
• GH and IGF-1 play roles in regulating metabolism, muscle growth, and fat distribution, particularly visceral fat (fat around organs).
• Tesamorelin helps reduce visceral fat by promoting lipolysis (fat breakdown) and inhibiting lipogenesis (fat production).
• HIV-associated lipodystrophy: Tesamorelin is specifically approved for reducing excess abdominal fat in adults with HIV who have lipodystrophy, a condition where fat is distributed unevenly in the body.
• Reduced Visceral Fat: Tesamorelin is effective in reducing visceral fat, which is linked to metabolic disorders and cardiovascular disease.
• Improved Body Composition: By reducing fat and preserving muscle, Tesamorelin may improve overall body composition.
• Metabolic Health: Tesamorelin can improve insulin sensitivity and lipid profiles, potentially benefiting individuals with metabolic disorders.
• Anti-Aging: Some research suggests Tesamorelin may have anti-aging effects, including improved energy levels and skin health, due to its impact on growth hormone. It works by stimulating the body’s natural production of growth hormone.
• It may also offer benefits like improved body composition and metabolic health.